Regeneron Pharmaceuticals, Inc.
REGN
$638.88
-$3.71-0.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 14.13B | 13.64B | 13.60B | 13.65B | 13.61B |
| Total Other Revenue | 791.90M | 702.60M | 643.40M | 559.40M | 480.00M |
| Total Revenue | 14.92B | 14.34B | 14.25B | 14.21B | 14.09B |
| Cost of Revenue | 8.37B | 7.95B | 7.72B | 7.48B | 7.21B |
| Gross Profit | 6.55B | 6.39B | 6.53B | 6.73B | 6.87B |
| SG&A Expenses | 2.71B | 2.70B | 2.72B | 2.77B | 2.90B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -10.00M | -10.00M | -10.00M | -- | -- |
| Total Operating Expenses | 11.08B | 10.64B | 10.42B | 10.26B | 10.11B |
| Operating Income | 3.84B | 3.70B | 3.82B | 3.96B | 3.98B |
| Income Before Tax | 5.16B | 5.23B | 5.15B | 4.87B | 4.98B |
| Income Tax Expenses | 733.50M | 725.80M | 567.10M | 416.20M | 484.90M |
| Earnings from Continuing Operations | 4.42K | 4.50K | 4.58K | 4.46K | 4.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.42B | 4.50B | 4.58B | 4.46B | 4.50B |
| EBIT | 3.84B | 3.70B | 3.82B | 3.96B | 3.98B |
| EBITDA | 4.38B | 4.25B | 4.35B | 4.47B | 4.47B |
| EPS Basic | 42.53 | 43.12 | 43.44 | 41.75 | 41.76 |
| Normalized Basic EPS | 33.11 | 32.21 | 26.79 | 27.36 | 27.12 |
| EPS Diluted | 41.04 | 41.56 | 41.77 | 39.69 | 39.29 |
| Normalized Diluted EPS | 31.89 | 30.99 | 25.72 | 25.98 | 25.52 |
| Average Basic Shares Outstanding | 415.60M | 418.30M | 423.00M | 427.50M | 430.50M |
| Average Diluted Shares Outstanding | 431.00M | 434.50M | 440.80M | 449.80M | 456.60M |
| Dividend Per Share | 3.58 | 3.52 | 2.64 | 1.76 | 0.88 |
| Payout Ratio | 8.46% | 8.22% | 6.06% | 4.18% | 2.08% |